Skip to content

Learning and Decision-making

How Does the Brain Learn About Positive and Negative Things?

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06014606
Enrollment
150
Registered
2023-08-28
Start date
2021-03-01
Completion date
2023-08-16
Last updated
2023-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Motivation

Brief summary

A fundamental aspect of daily life decision-making involves the evaluation of costs and benefits. Neural systems underlying cost-benefit evaluation have been extensively examined, but the specific role of different neurotransmitters remains unclear. Numerous studies suggest that both dopamine (DA) and norepinephrine (NE) are closely related to reinforcement learning, guided exploration/exploitation, and behavioural energisation, although no studies to date have investigated the distinct role of DA and NE on cost-benefit decision-making and learning in human subjects.

Interventions

DRUGplacebo

oral formulation

DRUGhaloperidol 2mg

oral formulation

DRUGpropranolol 40mg

oral formulation

Sponsors

Maastricht University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Masking description

double-blind (randomised) between-subjects design

Eligibility

Sex/Gender
ALL
Age
18 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* Willingness to sign an informed consent * Age between 18 and 35 * Body-Mass Index (BMI) between 17.5-30 * Availability for participation through the duration of the study

Exclusion criteria

* Diagnosis of a psychiatric or neurological disorder, including substance abuse or dependence (yes/no self-report - lifetime) * Use of any psychopharmacological treatment 3 weeks before the test day (yes/no self-report) * Use of any blood pressure medication (yes/no self-report - lifetime) * Pregnancy (confirmed via urine pregnancy test) or nursing (yes/no self-report) or have plans to get pregnant in the near future (yes/no self-report) (females only) * Diagnosis of a cardiac disease (medical questionnaire), obstructive respiratory disease (medical questionnaire), abnormal blood pressure (diastolic\< 60mmHg; systolic\< 90mmHg) (medical screening) * Chronic renal failure (medical questionnaire) * Hypothyroidism (medical questionnaire) * Diabetes (medical questionnaire) * Hypersensitivity to phenothiazines (medical questionnaire) * Diagnosis of a cardiac disease (medical questionnaire) * Alcohol consumption in the 24 hours before the test session starts (yes/no self-report) * Food intake less than 3 hours before the test day (yes/no self-report)

Design outcomes

Primary

MeasureTime frameDescription
Cost-benefit reinforcement learning performance~ 2.5 hours post-drug administration2-choice reinforcement learning task (based on Voulgaropoulou et al., 2021 PNEC)

Secondary

MeasureTime frameDescription
Effort-based decision-making~ 2 hours post-drug administrationmotivation to acquire rewards (e.g., Reddy et al. 2015)

Other

MeasureTime frameDescription
Physiology Ipre, +30 min., +60 min., +90 min., +120 min., +190 min. post-drug administrationHeart rate
Physiology IIpre, +30 min., +60 min., +90 min., +120 min., +190 min. post-drug administrationblood pressure

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026